Shots:
- Richter signed an asset purchase agreement with Janssen for Evra transdermal contraceptive patch assets outside the US. The total deal value is $263.5M
- The companies also signed a transitional business license agreement and a series of other related agreements to run the business without interruption during the period required to transfer the marketing authorizations to Richter
- The acquisition will strengthen Richter’s position in women’s healthcare and boost its existing female healthcare franchise globally. Evra (qw) is the first transdermal hormonal patch to be approved, as well as the first non-invasive form of birth control that, when used correctly, is 99% effective
Click here to read full press release/ article | Ref: Richter | Image: Richter
The post Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for 3.5M first appeared on PharmaShots.
